CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $82.28M, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
60.92MGBP82.28M · vs all stocks (USD)
Revenue (TTM)
0.00GBPvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.80xvs all stocks
52-Week Change
223.33%vs all stocks
Market Capitalization
60.92MGBP82.28M · vs all stocks (USD)
Enterprise Value
50.81MGBP68.62M · vs all stocks (USD)
Forward P/E
-8.40xvs Biotechnology peers
Price to Book (MRQ)
6.65xvs Biotechnology peers
Enterprise to EBITDA
-8.10xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-39.20%vs Biotechnology peers
Return on Equity (TTM)
-63.72%vs Biotechnology peers
Revenue (TTM)
0.00GBPvs all stocks (USD)
Revenue per Share (TTM)
0.00GBPUpdated Aug 7, 2026Gross Profit (TTM)
0.00GBPvs all stocks (USD)
EBITDA (TTM)
-6.27MGBP-8.47M · vs all stocks (USD)
Net Income (TTM)
-5.70MGBP-7.69M · vs all stocks (USD)
Operating Cash Flow (TTM)
-4.76MGBP-6.43M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-2.88MGBP-3.89M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Aug 7, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
0.00GBPFY2024 · Dec 31, 2024Cost of Goods Sold
0.00GBPFY2024 · Dec 31, 2024Gross Profit
0.00GBPFY2024 · Dec 31, 2024Operating Income
-6.11MGBP-8.25M · vs all stocks (USD)
Pre-tax Income
-5.94MGBPFY2024 · Dec 31, 2024Income Tax Expense
-154.00KGBPFY2024 · Dec 31, 2024Net Income
-5.79MGBPFY2024 · Dec 31, 2024EBIT
-6.11MGBPFY2024 · Dec 31, 2024EBITDA (Income Statement)
-5.74MGBPFY2024 · Dec 31, 2024Research & Development
1.38MGBPFY2024 · Dec 31, 2024Selling, General & Administrative
5.26MGBPFY2024 · Dec 31, 2024Non-operating Interest Income
428.00KGBPFY2024 · Dec 31, 2024EPS (Basic)
-0.0116GBPFY2024 · Dec 31, 2024EPS (Diluted)
-0.0116GBPFY2024 · Dec 31, 2024Basic Shares Outstanding
500.00MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
500.00MSharesFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00GBPFY2024 · Dec 31, 2024Operating Cash Flow
-5.60MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
7.82MGBPFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-5.94MGBPFY2024 · Dec 31, 2024Stock-based Compensation
621.00KGBPFY2024 · Dec 31, 2024Other Non-cash Items
-428.00KGBPFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
147.00KGBPFY2024 · Dec 31, 2024Net Intangibles (CF)
-129.00KGBPFY2024 · Dec 31, 2024Shares Outstanding
697.20MSharesUpdated Aug 7, 2026Float Shares
515.91MSharesUpdated Aug 7, 2026% Held by Insiders
38.16%vs all stocks
% Held by Institutions
4.37%vs all stocks
Total Cash (MRQ)
7.71MGBP10.42M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0110GBPUpdated Aug 7, 2026Total Debt (MRQ)
0.00GBPvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xvs Biotechnology peers
Current Ratio (MRQ)
6.17xvs Biotechnology peers
Book Value per Share (MRQ)
0.0120GBPUpdated Aug 7, 2026Total Assets
10.25MGBP13.84M · vs all stocks (USD)
Total Current Assets
8.56MGBPFY2024 · Dec 31, 2024Total Liabilities
974.00KGBPFY2024 · Dec 31, 2024Total Non-current Assets
1.68MGBPFY2024 · Dec 31, 2024Total Non-current Liabilities
0.00GBPFY2024 · Dec 31, 2024Total Current Liabilities
974.00KGBPFY2024 · Dec 31, 2024Cash
1.21MGBPFY2024 · Dec 31, 2024Cash Equivalents
6.61MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents
7.82MGBPFY2024 · Dec 31, 2024Accounts Receivable
20.00KGBPFY2024 · Dec 31, 2024Accounts Payable
165.00KGBPFY2024 · Dec 31, 2024Common Stock (Book)
100.00KGBPFY2024 · Dec 31, 2024Retained Earnings
-16.74MGBPFY2024 · Dec 31, 2024Total Shareholders' Equity
9.27MGBP12.52M · vs all stocks (USD)
52-Week Low
2.50GBXUpdated Aug 7, 202652-Week High
9.00GBXUpdated Aug 7, 202652-Week Change
223.33%vs all stocks
Beta
1.80xvs all stocks
50-Day MA
6.87GBXUpdated Aug 7, 2026200-Day MA
4.91GBXUpdated Aug 7, 2026Avg 10-Day Volume
2.43MSharesUpdated Aug 7, 2026Avg 30-Day Volume
2.69MSharesUpdated Aug 7, 2026Diluted EPS (TTM)
-0.0100GBPUpdated Aug 7, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $82.28M, lower than 95% of all stocks globallySignificant
Market cap (USD): 82,277,368.226Global P5: 279,010,173.859
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 32,166,921.735
Companies that share the same coordination system — how they create, deliver, or capture value.
Curiosis Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tenax Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eco Animal Health Group PLC
Tier 1ProductionApproval-Gated PipelineRule
Creo Medical Group plc
Tier 1ProductionApproval-Gated PipelineRule
Bonus BioGroup Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kala Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Y-Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk
Engene Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Polaryx Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule